SPA
AVNS

Sherbrooke Park Advisers’s Avanos Medical AVNS Stock Holding History

Sherbrooke Park Advisers’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18,512
Closed -$227K – 524
2025
Q2 		$227K Buy
18,512
+568
+3% +$7.14K 0.1% 365
2025
Q1 		$257K Buy
+17,944
New +$280K 0.12% 345
2024
Q4 		– Sell
-21,962
Closed -$528K – 774
2024
Q3 		$528K Buy
+21,962
New +$502K 0.12% 291

Other funds holding AVNS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Sherbrooke Park Advisers's AVNS Position: Q3 2025 in Review

Sherbrooke Park Advisers sold out of Avanos Medical (AVNS) in Q3 2025, closing a stake of 18,512 shares — an estimated $227K sold.

Sherbrooke Park Advisers first reported a position in AVNS in Q3 2024 and held it in 3 quarters. The position peaked at $528K in Q3 2024. 276 funds tracked by Wall St. Rank hold AVNS as of Q3 2025.

  • Sherbrooke Park Advisers reported no remaining Avanos Medical position as of Q3 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 18,512 Avanos Medical shares in Q3 2025, an estimated $227K.
  • Sherbrooke Park Advisers first reported a position in Avanos Medical in Q3 2024 and held it in 3 quarters.
  • Sherbrooke Park Advisers's Avanos Medical position peaked at $528K in Q3 2024.
  • 276 funds tracked by Wall St. Rank held Avanos Medical as of Q3 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.